Arachidonic acid and docosahexaenoic acid suppress osteoclast formation and activity in human CD14+ monocytes, in vitro

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Kasonga, Abe E ^a   Deepak, Vishwa ^a   Kruger, Marlena C ^b,c   Coetzee, Magdalena ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b MASSEY UNIVERSITY   (New Zealand)

^c UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACTIN; ARACHIDONIC ACID; CALCITONIN RECEPTOR; CD14 ANTIGEN; COLONY STIMULATING FACTOR; DOCOSAHEXAENOIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; VITRONECTIN RECEPTOR; ACID PHOSPHATASE; CONDITIONED MEDIUM; ISOENZYME;

ARTICLE; CELL ACTIVITY; CELL COUNT; CELL DIFFERENTIATION; CELL ISOLATION; CELL MATURATION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MONOCYTE; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN EXPRESSION; CELL CULTURE; CONDITIONED MEDIUM; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; OSTEOCLAST;

ACID PHOSPHATASE; ANTIGENS, CD14; ARACHIDONIC ACID; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; DOCOSAHEXAENOIC ACIDS; GENE EXPRESSION; HUMANS; IN VITRO TECHNIQUES; ISOENZYMES; MONOCYTES; OSTEOCLASTS; TARTRATE-RESISTANT ACID PHOSPHATASE;

EID: 84929996350     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125145     Document Type: Article

References (54)

1. Väänänen HK, Zhao H, Mulari M, Halleen JM. The cell biology of osteoclast function. J Cell Sci. 2000; 113: 377-381. PMID: 10639325
2. Henriksen K, Bollerslev J, Everts V, Karsdal MA. Osteoclast activity and subtypes as a function of physiology and pathology-implications for future treatments of osteoporosis. Endocr Rev. 2011; 32: 31-63. doi: 10.1210/er.2010-0006 PMID: 20851921
3. Väänänen HK, Laitala-Leinonen T. Osteoclast lineage and function. Arch Biochem Biophys. 2008; 473: 132-138. doi: 10.1016/j.abb.2008.03.037 PMID: 18424258
4. Poulsen RC, Moughan PJ, Kruger MC. Long-chain polyunsaturated fatty acids and the regulation of bone metabolism. Exp Biol Med. 2007; 232: 1275-1288. PMID: 17959840
5. Ferlin A, Pepe A, Facciolli A, Gianesello L, Foresta C. Relaxin stimulates osteoclast differentiation and activation. Bone. 2010; 46: 504-513. doi: 10.1016/j.bone.2009.10.007 PMID: 19833242
6. Agrawal A, Buckley KA, Bowers K, Furber M, Gallagher JA, Gartland A. The effects of P2X7 receptor antagonists on the formation and function of human osteoclasts in vitro. Purinergic Signal. 2010; 6: 307-315. doi: 10.1007/s11302-010-9181-z PMID: 21103214
7. Bar-Shavit Z. The osteoclast: a multinucleated, hematopoietic-origin, bone-resorbing osteoimmune cell. J Cell Biochem. 2007; 102: 1130-1139. PMID: 17955494
8. Sun D, Krishnan A, Zaman K, Lawrence R, Bhattacharya A, Fernandes G. Dietary n-3 fatty acids decrease osteoclastogenesis and loss of bone mass in ovariectomized mice. J Bone Miner Res. 2003; 18: 1206-1216. PMID: 12854830
9. Choia HK, Kimb TH, Jhonb GL, Leea SY. Reactive oxygen species regulate M-CSF-induced monocyte/macrophage proliferation through SHP1 oxidation. Cell Signal. 2011; 23: 1633-1639. doi: 10.1016/j.cellsig.2011.05.017 PMID: 21664461
10. Kim K, Lee SH, Ha Kim J, Choi Y, Kim N. NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol Endocrinol. 2008; 22: 176-185. PMID: 17885208
11. Faccio R, Choi Y, Teitelbaum SL, Takayanagi H. The Osteoclast: The Pioneer of Osteoimmunology. In: Lorenzo JA, Choi Y, Horowitz M, Takayanagi H, editors. Osteoimmunology. London: Academic Press; 2011. pp. 142-175.
12. Shomali T, Rezaian M, Rassouli A, Asadi F. Effect of eicosapentaenoic acid on bone changes due to ethylprednisolone in rats. Basic Clin Pharmacol Toxicol. 2009; 105: 46-50. doi: 10.1111/j.1742-7843.2009.00393.x PMID: 19302435
13. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr. 2002; 21: 495-505. PMID: 12480795
14. Kurlak LO, Stephenson TJ. Plausible explanations for effects of long chain polyunsaturated fatty acids (LCPUFA) on neonates. Arch Dis Child Fetal Neonatal Ed. 1999; 80: 148-154. PMID: 10325796
15. Farina EK, Kiel DP, Roubenoff R, Schaefer EJ, Cupples LA, Tucker KL. Protective effects of fish intake and interactive effects of long-chain polyunsaturated fatty acid intakes on hip bone mineral density in older adults: the Framingham Osteoporosis Study. Am J Clin Nutr. 2011; 93: 1142-1151. doi: 10.3945/ajcn.110.005926 PMID: 21367955
16. Al-Nouri DM, Al-Khalifa AS, Shahidi F. Long-term supplementation of dietary omega-6/omega-3 ratios alters bone marrow fatty acid and biomarkers of bone metabolism in growing rabbits. J Funct Food. 2012; 4: 584-593.
17. Bonnet N, Ferrari SL. Effects of long-term supplementation with omega-3 fatty acids on longitudinal changes in bone mass and microstructure in mice. J Nutr Biochem. 2011; 22: 665-672. doi: 10.1016/j.jnutbio.2010.05.006 PMID: 21036590
18. Hutchins-Wiese HL, Picho K, Watkins BA, Li Y, Tannenbaum S, Claffey K, et al. High-dose eicosapentaenoic acid and docosahexaenoic acid supplementation reduces bone resorption in postmenopausal breast cancer survivors on aromatase inhibitors: a pilot study. Nutr Cancer. 2014; 66: 68-76. doi: 10.1080/01635581.2014.847964 PMID: 24274259
19. Högström M, Nordström P, Nordström A. n-3 Fatty acids are positively associated with peak bone mineral density and bone accrual in healthy men: the NO2 Study. Am J Clin Nutr. 2007; 85: 803-807. PMID: 17344503
20. Tartibian B, Hajizadeh Maleki B, Kanaley J, Sadeghi K. Long-term aerobic exercise and omega-3 supplementation modulate osteoporosis through inflammatory mechanisms in post-menopausal women: a randomized, repeated measures study. Nutr Metab. 2011; 8: 8-71.
21. Farina EK, Kiel DP, Roubenoff R, Schaefer EJ, Cupples LA, Tucker KL. Dietary intakes of arachidonic acid and alpha-linolenic acid are associated with reduced risk of hip fracture in older adults. J Nutr. 2011; 141: 1146-1153. doi: 10.3945/jn.110.133728 PMID: 21508210
22. Bassey EJ, Littlewood JJ, Rothwell MC, Pye DW. Lack of effect of supplementation with essential fatty acids on bone mineral density in healthy pre- and postmenopausal women: two randomized controlled trials of Efacal v. calcium alone. Br J Nutr. 2000; 83: 629-635. PMID: 10911771
23. Sharif PS, Asalforoush M, Ameri F, Larijani B, Abdollahi M. The effect of n-3 fatty acids on bone biomarkers in Iranian postmenopausal osteoporotic women: a randomized clinical trial. Age. 2010; 32: 179-186. doi: 10.1007/s11357-009-9122-3 PMID: 19967563
24. McLaughlin V, Reeves KW, Bertone-Johnson E. Fatty acid consumption and the risk of osteoporotic fracture. Nutr Rev. 2013; 71: 600-610. doi: 10.1111/nure.12043 PMID: 24032364
25. Cornish J, MacGibbon A, Lin JM, Watson M, Callon KE, Tong PC, et al. Modulation of osteoclastogenesis by fatty acids. Endocrinology. 2008; 149: 5688-5695. doi: 10.1210/en.2008-0111 PMID: 18617622
26. Yuan J, Akiyama M, Nakahama K, Sato T, Uematsu H, Morita I. The effects of polyunsaturated fatty acids and their metabolites on osteoclastogenesis in vitro. Prostaglandins Other Lipid Mediat. 2010; 92: 85-90. doi: 10.1016/j.prostaglandins.2010.04.001 PMID: 20394833
27. Boeyens JCA, Deepak V, Chua WH, Kruger MC, Joubert AM, Coetzee M. Effects of n3- and n6-polyunsaturated fatty acids on RANKL-induced osteoclast differentiation of RAW264.7 cells: A comparative in vitro study. Nutrients. 2014; 6: 2584-2601. doi: 10.3390/nu6072584 PMID: 25010555
28. Rahman MM, Bhattacharya A, Fernandes G. Docosahexaenoic acid is more potent inhibitor of osteoclast differentiation in RAW 264.7 cells than eicosapentaenoic acid. J Cell Physiol. 2008; 214: 201-209. PMID: 17929247
29. Agrawal A, Gallagher JA, Gartland A. Human osteoclast culture and phenotypic characterization. Methods Mol Biol. 2012; 806: 357-375. doi: 10.1007/978-1-61779-367-7-23 PMID: 22057463
30. Henriksen K, Flores C, Thomsen JS, Bruel AM, Thudium CS, Neutzsky-Wulff AV, et al. Dissociation of bone resorption and bone formation in adult mice with a non-functional V-ATPase in osteoclasts leads to increased bone strength. PLOS ONE. 2011; 6: e27482. doi: 10.1371/journal.pone.0027482 PMID: 22087326
31. Walsh CA, Beresford JN, Birch MA, Boothroyd B, Gallagher JA. Application of reflected light microscopy to identify and quantitate resorption by isolated osteoclasts. J Bone Miner Res. 1991; 6: 661-671. PMID: 1950671
32. Rasband WS. ImageJ. 2014. Available: http://imageJ.nih.gov/ijl.
33. Costa-Rodrigues J, Teixeira CA, Sampaio P, Fernandes MH. Characterisation of the osteoclastogenic potential of human osteoblastic and fibroblastic conditioned media. J Cell Biochem. 2010; 109: 205-216. doi: 10.1002/jcb.22398 PMID: 19911374
34. Deepak V, Kasonga A, Kruger MC, Coetzee M. Inhibitory effects of eugenol on RANKL-induced osteoclast formation via attenuation of NF-kappaB and MAPK pathways. Connect Tissue Res. 2014 Dec 11; doi: 10.3109/03008207.03002014.03989320
35. Rissanen JP, Suominen MI, Peng Z, Halleen JM. Secreted tartrate-resistant acid phosphatase 5b is a Marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model. Calcif Tissue Int. 2008; 82: 108-115. PMID: 18084692
36. Lepidi S, Kenagy RD, Raines EW, Chiu ES, Chait A, Ross R, et al. MMP9 production by human monocyte-derived macrophages is decreased on polymerized type I collagen. J Vasc Surg. 2001; 34: 1111-1118. PMID: 11743569
37. Allard-Chamard H, Dufort P, Haroun S, de Brum-Fernandes AJ. Cytosolic phospholipase A2 and eicosanoids modulate life, death and function of human osteoclasts in vitro. Prostaglandins Leukot Essent Fatty Acids. 2014; 90: 117-123. doi: 10.1016/j.plefa.2013.12.009 PMID: 24508380
38. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011; 58: 2047-2067. doi: 10.1016/j.jacc.2011.06.063 PMID: 22051327
39. Xing L, Chen D, Boyce BF. Mice deficient in NF-κB p50 and p52 or RANK have defective growth plate formation and post-natal dwarfism. Bone Res. 2013; 4: 336-345. PMID: 25264493
40. Sørensen MG, Henriksen K, Schaller S, Henriksen DB, Nielsen FC, Dziegiel MH, et al. Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood. J Bone Miner Metab. 2007; 25: 36-45. PMID: 17187192
41. Goto T, Yamaza T, Tanaka T. Cathepsins in the osteoclast. J Electron Microsc. 2003; 52: 551-558. PMID: 14756243
42. Drake FH, Dodds RA, James IE, Connor JR, Debouck C, Richardson S, et al. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem. 1996; 271: 12511-12516. PMID: 8647859
43. Johnson MR, Polymeropoulos MH, Vos HL, Ortiz de Luna RI, Francomano CA. A nonsense mutation in the cathepsin K gene observed in a family with pycnodysostosis. Genome Res. 1996; 6: 1050-1055. PMID: 8938428
44. Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM, Väänänen HK. Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab. 2006; 52: 499-509. PMID: 17078477
45. Oddie GW, Schenk G, Angel NZ, Walsh N, Guddat LW, de Jersey J, et al. Structure, function, and regulation of tartrate-resistant acid phosphatase. Bone. 2000; 27: 575-584. PMID: 11062342
46. Sundaram K, Nishimura R, Senn J, Youssef RF, London SD, Reddy SV. RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation. Exp Cell Res. 2007; 313: 168-178. PMID: 17084841
47. Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell. 1998; 93: 411-422. PMID: 9590175
48. Nakamura I, Duong le T, Rodan SB, Rodan GA. Involvement of alpha(v)beta3 integrins in osteoclast function. J Bone Miner Metab. 2007; 25: 337-344. PMID: 17968485
49. Virtanen JK, Mozaffarian D, Willett WC, Feskanich D. Dietary intake of polyunsaturated fatty acids and risk of hip fracture in men and women. Osteoporos Int. 2012; 23: 2615-2624. doi: 10.1007/s00198-012-1903-3 PMID: 22270860
50. Hardy R, Cooper MS. Bone loss in inflammatory disorders. J Endocrinol. 2009; 201: 309-320. doi: 10.1677/JOE-08-0568 PMID: 19443863
51. Mundy GR. Osteoporosis and inflammation. Nutr Rev. 2007; 65: S147-151. PMID: 18240539
52. Corwin RL. Effects of dietary fats on bone health in advanced age. Prostaglandins Leukot Essent Fatty Acids. 2003; 68: 379-386. PMID: 12798658
53. Kruger MC, Coetzee M, Haag M, Weiler H. Long-chain polyunsaturated fatty acids: selected mechanisms of action on bone. Prog Lipid Res. 2010; 49: 438-449. doi: 10.1016/j.plipres.2010.06.002 PMID: 20600307
54. Gewirtz AT, Collier-Hyams LS, Young AN, Kucharzik T, Guilford WJ, Parkinson JF, et al. Lipoxin a4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J Immunol. 2002; 168: 5260-5267. PMID: 11994483